606 results match your criteria Diabetes Therapy [Journal]


Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.

Diabetes Ther 2019 Feb 20. Epub 2019 Feb 20.

Quantitative Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark.

Introduction: The aim of the present analysis was to characterise the absorption, distribution and elimination of semaglutide by means of population pharmacokinetic (PK) models using data from nine clinical pharmacology trials conducted in both healthy subjects and those with type 2 diabetes.

Methods: Data were obtained from trials with subcutaneous and intravenous administration of semaglutide that utilised frequent PK sampling and included a total of 353 subjects with 10,573 concentration values.

Results: Semaglutide PK properties across trials, drug product strengths and populations were well characterised by a two-compartment model with first-order absorption and elimination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0581-yDOI Listing
February 2019

C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.

Diabetes Ther 2019 Feb 20. Epub 2019 Feb 20.

Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Introduction: Despite the widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1ras) to improve glycemic regulation, with a low risk of hypoglycemia and weight reduction, their effectiveness varies among individuals. This study aimed to identify predictors of the efficacy of GLP-1ra on Hemoglobin A1c (HbA1c) in patients with insulin-independent diabetes.

Methods: In total, 58 patients with insulin-independent diabetes were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0586-6DOI Listing
February 2019

Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).

Diabetes Ther 2019 Feb 20. Epub 2019 Feb 20.

Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Introduction: Despite the continuously growing number of therapeutic options for patients with type 2 diabetes mellitus (T2DM), a large percentage of these individuals fail to achieve their glycated hemoglobin (HbA1c) target. The aim of this study was to determine the change in metabolic control in insulin-naïve T2DM patients inadequately controlled with oral antidiabetic drugs (OADs) at 6 months after initiating basal insulin treatment as add-on to existing OADs.

Methods: This was a non-interventional prospective study conducted from June 2013 to December 2014 in 137 centers in the Czech Republic under routine clinical practice conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0584-8DOI Listing
February 2019

Quality of Life is Markedly Impaired by Rheumatological and Skin Manifestations in Patients with Type 1 Diabetes: A Questionnaire Survey.

Diabetes Ther 2019 Feb 19. Epub 2019 Feb 19.

Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Introduction: To estimate lifetime prevalence of diabetes-related upper limb and non-acquired skin manifestations in a representative type 1 diabetes (T1D) population and to identify associations between these conditions and quality of life.

Methods: A questionnaire on these complications and measures of quality of life (World Health Organization-Five Well-Being Index [WHO-5]), depression, and diabetes-specific burden (Problem Areas in Diabetes [PAID] scale) was sent to all T1D patients in a Danish clinic (N = 583).

Results: The response rate was 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0587-5DOI Listing
February 2019

Improvement in Quality of Care for Patients with Type 2 Diabetes in Hungary Between 2008 and 2016: Results from Two Population-Based Representative Surveys.

Diabetes Ther 2019 Feb 15. Epub 2019 Feb 15.

Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary.

Introduction: Due to the increasing trends of recent decades, diabetes prevalence has reached a frequency of 1/11 adults worldwide. However, this disadvantageous trend has not been accompanied by worsened outcome indicators; better short-term (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0582-xDOI Listing
February 2019
1 Read

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.

Diabetes Ther 2019 Feb 14. Epub 2019 Feb 14.

Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Introduction: The LIGHTNING study applied conventional and advanced analytic approaches to model, predict, and compare hypoglycemia rates of people with type 2 diabetes (T2DM) on insulin glargine 300 U/ml (Gla-300) with those on first-generation (insulin glargine 100 U/ml [Gla-100]; insulin detemir [IDet]) or second-generation (insulin degludec [IDeg]) basal-insulin (BI) analogs, utilizing a large real-world database.

Methods: Data were collected between 1 January 2007 and 31 March 2017 from the Optum Humedica US electronic health records [EHR] database. Patient-treatments, the period during which a patient used a specific BI, were analyzed for patients who switched from a prior BI or those who newly initiated BI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0568-8DOI Listing
February 2019

Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the LIGHTNING Study.

Diabetes Ther 2019 Feb 14. Epub 2019 Feb 14.

Sanofi, Bridgewater, NJ, USA.

Introduction: Hypoglycemia remains a global burden and a limiting factor in the glycemic management of people with diabetes using basal insulins or oral antihyperglycemic drugs. Hypoglycemia data gleaned from randomized controlled trials (RCTs) have limited generalizability, as the strict RCT methodology and inclusion criteria do not fully reflect the real-world clinical picture. Therefore, real-world evidence, gathered from sources including electronic health records (EHR), is increasingly recognized as an important adjunct to RCTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0567-9DOI Listing
February 2019

The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.

Diabetes Ther 2019 Feb 13. Epub 2019 Feb 13.

Diabetes Research Centre, University of Leicester, Leicester, UK.

There is currently a worldwide epidemic of type 2 diabetes (T2D) that is predicted to increase substantially in the next few years. With 80% of the global T2D population living in low to middle-income countries, there are issues with cost and of access to appropriate medicines. The objective of this symposium was to provide an overview of the efficacy and safety of glucose-lowering drugs, focussing in particular on sulfonylureas (SUs) in patients with T2D using data taken from both randomised controlled trials (RCTs) and real-world studies, the application of strategies to ensure optimal patient adherence and clinical outcomes, and the optimal use of SUs in terms of dose adjustment and agent choice to ensure the best clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0573-yDOI Listing
February 2019

Association of the Serum Total Cholesterol to Triglyceride Ratio with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes: A Community-Based Study.

Diabetes Ther 2019 Feb 13. Epub 2019 Feb 13.

Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

Introduction: The relationship of total cholesterol (TC) or triglyceride (TG) to diabetic retinopathy (DR) has proven difficult to determine. In addition, there is no report of any study of the correlation between the TC/TG ratio and DR. This study was therefore undertaken to investigate the relationship between the TC/TG ratio and DR in Chinese adults with type 2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0579-5DOI Listing
February 2019
1 Read

Use of Continuous Glucose Monitoring in People with Type 1 Diabetes: Perspectives of Two People with Diabetes and Physician Perspective.

Diabetes Ther 2019 Feb 8. Epub 2019 Feb 8.

Department of Diabetes and Endocrinology, Guy's and St Thomas NHS Foundation Trust, London, UK.

This article details perspectives from two individuals with type 1 diabetes (T1DM) who use continuous glucose monitoring (CGM) devices to improve their quality of life and self-management of diabetes. It provides a unique perspective of how CGM can make living with T1DM safer and easier, while improving the time spent in the target glucose range (time in range). The perspectives of these two individuals highlight both the immediate need for improved access and support for CGM as well as the need for an understanding of the benefits of using non-medically approved technologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0576-8DOI Listing
February 2019

Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications.

Diabetes Ther 2019 Feb 8. Epub 2019 Feb 8.

Heart of England NHS Foundation Trust, Birmingham, UK.

Introduction: The increasing prevalence of type 2 diabetes (T2DM) in the UK imposes a significant burden on the National Health Service (NHS). Despite the availability of effective treatments, the loss of glycaemic control over time results in significant comorbidities, including nephropathy, neuropathy and retinopathy. The cost of treating these microvascular complications has not been well documented, and this study aimed to provide an accurate assessment of the healthcare resource utilisation (HCRU) associated with managing T2DM and its complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0548-4DOI Listing
February 2019
1 Read

Diagnostic Accuracy of Glycated Haemoglobin and Average Glucose Values in Type 2 Diabetes Mellitus Treated with Premixed Insulin.

Diabetes Ther 2019 Feb 8. Epub 2019 Feb 8.

Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland.

Introduction: Studies assessing the relationship between glycated haemoglobin (HbA1c) and average blood glucose (ABG) were conducted in small groups of patients on different treatments and may be biased for these reasons. The aim of the study was to assess the relationship between HbA1c and ABG in a large group of type 2 diabetes patients treated with premix insulin.

Methods: In 4257 patients treated with premixed insulin, the parallel point-of-care assessment of HbA1c and ABG from the preceding 90 days (ABG90), calculated automatically from all values measured by the glucometer, was performed twice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0570-1DOI Listing
February 2019
2 Reads

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan.

Diabetes Ther 2019 Feb 7. Epub 2019 Feb 7.

Astellas Pharma Inc., Tokyo, Japan.

Introduction: The aim of this study was to evaluate the characteristics of new users of sodium glucose co-transporter-2 inhibitors (SGLT2i) in comparison with those of new users of other oral antidiabetic drugs (OADs) using data retrieved from three administrative databases in Japan.

Methods: This study included adult patients from each database who started an OAD between 2014 and 2017. Outpatients who started SGLT2i therapy were included in the SGLT2i cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0577-7DOI Listing
February 2019

Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland.

Diabetes Ther 2019 Feb 7. Epub 2019 Feb 7.

Nurmijärvi Health Centre, Nurmijärvi, Finland.

Introduction: Although primarily utilized in type 1 diabetes, continuous subcutaneous insulin infusion (CSII) represents a useful treatment alternative for patients with type 2 diabetes who are unable to achieve good glycemic control despite optimization of multiple daily injections (MDI). The aim of the analysis reported here was to investigate the long-term cost-effectiveness of CSII versus MDI in type 2 diabetes patients with poor glycemic control in Finland.

Methods: The IQVIA CORE Diabetes Model was used to make long-term projections of the clinical and economic outcomes associated with CSII use in type 2 diabetes, based on clinical input data from the OpT2mise trial, which showed that CSII was associated with a 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0575-9DOI Listing
February 2019
1 Read

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review.

Diabetes Ther 2019 Feb 6. Epub 2019 Feb 6.

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Diabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0580-zDOI Listing
February 2019

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis.

Diabetes Ther 2019 Feb 6. Epub 2019 Feb 6.

Department of Hemopathology, Puyang City Oilfield General Hospital, Puyang City, Henan, People's Republic of China.

Introduction: Studies of the effects of stem cell therapy on type 2 diabetes mellitus (T2DM) have not reached consistent results. Our meta-analysis aimed to systematically evaluate the efficacy of autologous bone marrow-derived stem cells (ABM-MNCs) on T2DM.

Methods: We systematically searched PubMed, EMBASE, Web of Science, and the Cochrane Library for studies published between 1980 and May 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0578-6DOI Listing
February 2019

Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project.

Diabetes Ther 2019 Feb 5. Epub 2019 Feb 5.

Mellitus Health Inc., Los Angeles, CA, USA.

Introduction: Primary care physicians are often challenged to adjust insulin doses. To facilitate this process, we evaluated in a safety net clinic the work flow and glycemic effects of remote glucose monitoring utilizing Federal Drug Administration (FDA) cleared, Conformité Européenne (CE) registered software that contained computerized algorithms for insulin dose adjustments to help clinicians make dosing decisions for insulin-requiring patients.

Methods: Patients taking insulin for at least 6 months with HbA1 levels of at least 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0565-yDOI Listing
February 2019

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians.

Diabetes Ther 2019 Jan 31. Epub 2019 Jan 31.

Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.

The current diabetes management strategies not only aim at controlling glycaemic parameters but also necessitate continuous medical care along with multifactorial risk reduction through a comprehensive management concept. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of evolving antidiabetic agents that have the potential to play a pivotal role in the comprehensive management of patients with diabetes due to their diverse beneficial effects. SGLT2i provide moderate glycaemic control, considerable body weight and blood pressure reduction, and thus have the ability to lower the risk of macrovascular and microvascular complications. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0562-1
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0562-1DOI Listing
January 2019
4 Reads

Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study.

Diabetes Ther 2019 Jan 31. Epub 2019 Jan 31.

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Sydney, Australia.

Introduction: Optimising patient adherence to prescribed lifestyle interventions to achieve improved blood glucose control remains a challenge. Combined use of real-time continuous glucose monitoring systems (RT-CGM) may promote improved glycaemic control. This pilot study examines the effects of a prescriptive lifestyle modification programme when combined with RT-CGM on blood glucose control and cardiovascular disease risk markers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0572-z
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0572-zDOI Listing
January 2019
1 Read

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.

Diabetes Ther 2019 Jan 31. Epub 2019 Jan 31.

Ossian Health Economics and Communications, Basel, Switzerland.

Introduction: Few patients with type 2 diabetes mellitus (T2DM) achieve recommended glycemic control targets in the Czech Republic. Novel therapies, such as fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 receptor agonists, may contribute to better glycemic control. In the analysis presented here, the present analysis assessed the long-term cost-effectiveness of two fixed-ratio combinations, IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), for the treatment of patients with T2DM inadequately controlled with basal insulin from a healthcare payer perspective in the Czech Republic. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0569-7
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0569-7DOI Listing
January 2019
3 Reads

A Practical Guide to Delivering Nutritional Advice to People with Diabetes.

Authors:
Pamela A Dyson

Diabetes Ther 2019 Jan 31. Epub 2019 Jan 31.

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.

Dietary advice is fundamental to the management of diabetes. Although ideally such advice should be delivered by a state-registered dietitian, it is more usually delivered by other health professionals. The primary focus for those with type 1 diabetes is carbohydrate counting and insulin adjustment and for the majority of people with type 2 diabetes, weight management is key. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0556-4DOI Listing
January 2019

Real-Time Sharing and Following of Continuous Glucose Monitoring Data in Youth.

Diabetes Ther 2019 Jan 30. Epub 2019 Jan 30.

Dexcom, Inc., San Diego, CA, USA.

Background: Those caring for children and adolescents with diabetes often use glucose concentration and trending information in management decisions. Some continuous glucose monitoring (CGM) systems offer real-time sharing and monitoring capabilities through mobile apps carried by the person with diabetes and the caregiver(s), respectively. Few large studies have explored real-world associations between sharing and following, CGM utilization, and glycemic outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0571-0DOI Listing
January 2019
1 Read

Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.

Diabetes Ther 2019 Jan 28. Epub 2019 Jan 28.

Pfizer, Tadworth, UK.

Introduction: Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0566-x
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0566-xDOI Listing
January 2019
11 Reads

Epidemiology, Quality of Life, and Costs Associated with Hypoglycemia in Patients with Diabetes in Spain: A Systematic Literature Review.

Diabetes Ther 2019 Jan 19. Epub 2019 Jan 19.

Department of Endocrinology and Nutrition, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Objective: To assess the burden of hypoglycemia in patients with diabetes mellitus (DM) in Spain, including epidemiological data and information relating to healthcare resource utilization (HRU) and costs, and patients' quality of life (QoL).

Methods: A systematic literature review (SLR) was conducted to identify studies that included original information on epidemiology, HRU and costs, and/or QoL associated with hypoglycemia in patients with DM in Spain, published in either Spanish or English, between January 2007 and April 2017.

Results: Fifteen articles, involving 14 studies, were identified in the SLR and included in the analysis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0563-0
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0563-0DOI Listing
January 2019
7 Reads

Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin.

Diabetes Ther 2019 Jan 18. Epub 2019 Jan 18.

Department of Endocrinology, East Hospital, Tongji University, Shanghai, 200120, People's Republic of China.

Introduction: Some type 2 diabetes (T2DM) patients treated with premixed insulin alone or in combination with oral glucose-lowering agents (without sulfonylureas) cannot reach the required glucose targets. Clinical studies have demonstrated that diabetes patients treated with sulfonylureas achieve stable glycemic control, with a low hypoglycemic rate. The aim of our study was to evaluate the efficacy and safety of therapy with the combination of premixed insulin and sulfonylureas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0564-zDOI Listing
January 2019
7 Reads

Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.

Diabetes Ther 2019 Jan 17. Epub 2019 Jan 17.

Ev. Krankenhaus Bethesda, 47053, Duisburg, Germany.

Introduction: Lixisenatide has been studied extensively in randomized clinical trials; however, data on its use in the real-life practice are scarce.

Methods: This study was a prospective, 26-week, multicenter, observational study conducted in Austrian diabetes centers and office-based practices to evaluate efficacy and safety of lixisenatide under real-life conditions in patients with type 2 diabetes.

Results: Out of 144 patients (mean BMI 36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0558-2DOI Listing
January 2019
2 Reads

Association Between Metformin and Sulfonylurea Monotherapies and Cancer Incidence: A Real-World Cohort Study in Shanghai, China.

Diabetes Ther 2019 Feb 8;10(1):245-258. Epub 2019 Jan 8.

Department of Health Economics, School of Public Health, Key Lab of Health Technology Assessment, National Health Commission, Fudan University, Shanghai, China.

Introduction: Previous studies have shown that patients with type 2 diabetes mellitus have an increased risk of cancer. The use of antidiabetic medication (ADM) may play an important role in the cancer development. The relationship between oral ADM and cancer incidence has not been investigated in type 2 diabetes mellitus patients in mainland China yet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0557-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349283PMC
February 2019
6 Reads

Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis.

Diabetes Ther 2019 Feb 7;10(1):229-243. Epub 2019 Jan 7.

Center for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.

Introduction: Treatment options and decisions are often based on the results of clinical trials. We have evaluated the public availability of results from completed, registered phase III clinical trials on diabetic nephropathy and current treatment options.

Methods: This was a cross-sectional analysis in which STrengthening the Reporting of OBservational studies in Epidemiology criteria were applied for design and analysis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0551-9
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0551-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349284PMC
February 2019
8 Reads

Impact of Insulin Injection and Infusion Routines on Lipohypertrophy and Glycemic Control in Children and Adults with Diabetes.

Diabetes Ther 2019 Feb 8;10(1):259-267. Epub 2019 Jan 8.

BD Diabetes Care, POB 13, Erembodegem-Dorp 86, 9320, Erembodegem, Belgium.

Introduction: Proper insulin injection/infusion is essential to optimize insulin absorption and action. Guidelines on insulin injection techniques are available. Lipohypertrophy (LH) is a local complication of insulin therapy, which results in erratic absorption and impaired glycemic control. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0561-7
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0561-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349294PMC
February 2019
12 Reads

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.

Diabetes Ther 2019 Feb 5;10(1):215-228. Epub 2019 Jan 5.

Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Introduction: To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM).

Methods: Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks. The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0560-8
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0560-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349295PMC
February 2019
10 Reads

Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose Monitoring System.

Diabetes Ther 2019 Feb 4;10(1):205-213. Epub 2019 Jan 4.

Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Introduction: The aim of this study was to determine the clinical efficacy of preprandial and postprandial Prandilin 25 (premixed insulin lispro 25) administration in patients with newly diagnosed type 2 diabetes mellitus (T2DM) using a continuous glucose monitoring (CGM) system.

Methods: This was a single-center, self-controlled comparative clinical trial. Newly diagnosed T2DM patients with hemoglobin A1c > 8. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0545-7
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0545-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349270PMC
February 2019
9 Reads

A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019.

Diabetes Ther 2019 Feb 2;10(1):1-3. Epub 2019 Jan 2.

University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0559-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349272PMC
February 2019
3 Reads

Lilly Insulin Glargine Versus Lantus in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5).

Diabetes Ther 2019 Feb 2;10(1):189-203. Epub 2019 Jan 2.

Doctors' Center Hospital, Manati, Puerto Rico.

Introduction: This study compared the efficacy and safety of similar U-100 insulin glargine products, namely, Lilly insulin glargine (LY IGlar; Basaglar) and the reference insulin glargine product (IGlar; Lantus), used once daily in combination with oral antihyperglycemic medications (OAMs) in adults with type 2 diabetes (T2D).

Methods: ELEMENT 5 was a phase III, randomized, multinational, open-label, treat-to-target, 24-week trial. Participants were insulin naïve (glycated hemoglobin [HbA1c] ≥ 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0549-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349279PMC
February 2019
2 Reads

Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.

Diabetes Ther 2019 Feb 21;10(1):311-321. Epub 2018 Dec 21.

Center of Diabetes, Endocrinology and Metabolism, Toho University Sakura Medical Center, Chiba, Japan.

Introduction: Sodium-dependent glucose transporter-2 (SGLT2) inhibitors such as dapagliflozin induce weight loss, but the mechanism is thought to involve loss of both body fat and skeletal muscle mass. The decrease in skeletal muscle mass may lead to worsening of insulin resistance in type 2 diabetes patients. On the other hand, formula diet (FD) is a low-calorie food containing low carbohydrates, low fat, and sufficient protein, vitamins, and minerals to support a healthy and balanced diet, and is used for the treatment of obesity or diabetes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0555-5
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0555-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349273PMC
February 2019
6 Reads

Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease.

Diabetes Ther 2019 Feb 18;10(1):277-281. Epub 2018 Dec 18.

Department of Acute and Specialty Care, University of Virginia School of Nursing, Charlottesville, VA, 22908, USA.

Introduction: Efforts to lower glycosylated hemoglobin (A1c) in patients with type 2 diabetes (T2D) are intended to reduce the risk of diabetic complications, but A1c is not the only factor contributing to this risk. Consequently, we re-analyzed published data from a broad-spectrum lifestyle intervention that lowered A1c to assess its effectiveness in lowering the overall risk of two complications of T2D, namely, coronary heart disease (CHD) and stroke.

Methods: Data from 37 adults who participated in a randomized clinical trial of a lifestyle intervention intended to reduce postprandial glucose (PPG) were re-analyzed for their pre- and post-treatment risk of CHD and stroke using the T2D-specific UK Prospective Diabetes Study (UKPDS) v2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0554-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349282PMC
February 2019
2 Reads

Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review.

Diabetes Ther 2019 Feb 18;10(1):35-56. Epub 2018 Dec 18.

Diabetes and Endocrinology Research, Department of Eye and Vision Sciences and Pain Research Institute, Institute of Ageing and Chronic Disease, University of Liverpool and Aintree University Hospital NHS Foundation Trust, Liverpool, UK.

Pregabalin is a first-line treatment in all major international guidelines on the management of painful diabetic neuropathy (pDPN). Treatment with pregabalin leads to a clinically meaningful improvement in pain scores, offers consistent relief of pain and has an acceptable tolerance level. Despite its efficacy in relieving neuropathic pain, more robust methods and comprehensive studies are required to evaluate its effects in relation to co-morbid anxiety and sleep interference in pDPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0550-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349275PMC
February 2019
5 Reads

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Diabetes Ther 2019 Feb 13;10(1):177-188. Epub 2018 Dec 13.

Clinical and Experimental Endocrinology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium.

Introduction: The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin aspart (faster aspart) relative to insulin aspart (IAsp) or basal-only insulin therapy on several efficacy and safety outcomes in people with diabetes.

Methods: Post hoc analysis of three randomised phase 3a trials in people with type 1 diabetes (T1D; onset 1) and type 2 diabetes (T2D; onset 2 and 3). Participants (N = 1686) were stratified according to baseline BMI (< 25 kg/m, 25-< 30 kg/m, ≥ 30 kg/m) or HbA1c (≤ 58 mmol/mol, > 58-< 64 mmol/mol, ≥ 64 mmol/mol; ≤ 7. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0553-7
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0553-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349278PMC
February 2019
4 Reads

High Dose Prednisolone Lowers Plasma Glycated Albumin Levels Compared to Actual Glycemic Control: A Retrospective Observational Study.

Diabetes Ther 2019 Feb 13;10(1):269-276. Epub 2018 Dec 13.

Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, 501-1194, Japan.

Introduction: Glycated hemoglobin (A1c) and glycated albumin (GA) are often used as indicators of glycemic control. In this study, we determined whether prednisolone (PSL) administration lowers plasma GA.

Methods: We investigated the factors affecting GA using multivariate analysis in 48 subjects with connective tissue diseases (CTDs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0552-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349290PMC
February 2019
4 Reads

Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Diabetes Ther 2019 Feb;10(1):329-331

Medical Clinic and Policlinic III at the University Hospital Dresden, Dresden, Germany.

In the original publication, the text in Table 2 stated 'Hypersensitivity to the active substance, to Ferinject, or to any of its excipients'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0546-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349274PMC
February 2019
9 Reads

Impact of Duodeno-Jejunal Bypass Liner (EndoBarrierTM) Implantation on Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus (T2DM): A Study Protocol for a Pilot Trial.

Diabetes Ther 2019 Feb 11;10(1):299-309. Epub 2018 Dec 11.

Divisions of Endocrinology and Diabetology, Division of Gastroenterology and Hepatology, Medizinische Universitat Graz, Graz, Austria.

Introduction: A 60-cm endoscopically implantable duodenal-jejunal bypass liner (Endobarrier™, GI Dynamics, Lexington, MA, USA) has been introduced as a therapeutic option to support weight loss for a selected group of obese subjects with type 2 diabetes mellitus (T2DM). The sleeve prevents contact between chyme and the intestinal mucosa of the upper gastrointestinal tract. The primary aim of this study is to elucidate the changes in insulin sensitivity and beta-cell function after EndoBarrier™ implantation in obese patients with T2DM; changes in gut permeability and gut microbiome are also to be examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0540-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349299PMC
February 2019
4 Reads

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.

Diabetes Ther 2019 Feb 11;10(1):21-33. Epub 2018 Dec 11.

Medical University of South Carolina, Charleston, SC, USA.

Introduction: iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (100 units/mL) and lixisenatide (33 μg/mL). This review evaluates the overall safety and adverse event (AE) profile of iGlarLixi in patients with type 2 diabetes.

Methods: We collated patient-level data from the phase 2 LixiLan proof-of-concept trial and the phase 3 LixiLan-L (insulin-experienced patients) and LixiLan-O (insulin-naïve patients) trials to evaluate AEs associated with iGlarLixi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0547-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349286PMC
February 2019
3 Reads

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.

Diabetes Ther 2019 Feb 7;10(1):159-176. Epub 2018 Dec 7.

Ossian Health Economics and Communications, Basel, Switzerland.

Introduction: Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0542-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349296PMC
February 2019
2 Reads

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis.

Diabetes Ther 2019 Feb 1;10(1):149-158. Epub 2018 Dec 1.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Introduction: Comparisons of the glycemic durability between thiazolidinediones (TZDs) and dipeptidyl peptidase-4 (DPP-4) inhibitors remain insufficient. This study aimed to find clues for the differences in glycemic durability between TZDs and DPP-4 inhibitors by comparing the insulin resistance and β-cell function among patients using these agents.

Methods: A total of 241 patients with type 2 diabetes mellitus (T2DM) treated with either pioglitazone (a TZD) or DPP-4 inhibitors as combination therapy with metformin for at least 1 year were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0541-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349276PMC
February 2019
2 Reads

A Single-Blinded Trial Using Resting-State Functional Magnetic Resonance Imaging of Brain Activity in Patients with Type 2 Diabetes and Painful Neuropathy.

Diabetes Ther 2019 Feb 30;10(1):135-147. Epub 2018 Nov 30.

Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

About two-thirds of patients with painful diabetic neuropathy (PDN) suffer from anxiety and/or depression disorders. However, the pathogenesis of PDN is unclear, in particular with respect to the mechanism associated with the central nervous system. We used the neuroimaging techniques of fraction amplitude of low-frequency fluctuation (fALFF) and regional homogeneity of resting-state functional magnetic resonance imaging (fMRI) to explore the brain activity in patients with PDN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0534-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349288PMC
February 2019
4 Reads

A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.

Diabetes Ther 2019 Feb 30;10(1):5-19. Epub 2018 Nov 30.

Eli Lilly and Company, Madrid, Spain.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and suppress glucagon release via the stimulation of GLP-1 receptors. Although all GLP-1 RAs share the same underlying mechanism of action, they differ in terms of formulations, administration, injection devices and dosages. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0535-9
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0535-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349277PMC
February 2019
9 Reads

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.

Diabetes Ther 2019 Feb;10(1):327

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

In the original publication, the text in abstract section under the 'Results' section is incorrectly published as 'higher proportion of patients reached a BeAM value < 55 mg/dL. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0544-8
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0544-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349285PMC
February 2019
23 Reads

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.

Diabetes Ther 2019 Feb 27;10(1):119-134. Epub 2018 Nov 27.

Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Introduction: There have been no studies directly comparing the effect of dipeptidyl peptidase-4 inhibitors with that of metformin on treatment-related quality of life (QOL) when used as first-line therapy in patients with type 2 diabetes mellitus (T2DM).

Methods: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Forty-four participants who failed to achieve target glycemic control with diet and exercise therapy were randomly allocated to receive linagliptin or metformin therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0539-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349297PMC
February 2019
3 Reads

Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.

Diabetes Ther 2019 Feb 24;10(1):107-118. Epub 2018 Nov 24.

Diabetes Research Unit Cymru, Swansea University, ABM University Health Board, Swansea, UK.

Introduction: The majority of elderly patients (≥ 65 years of age) with type 2 diabetes mellitus (T2DM) will eventually require insulin therapy, but they are particularly vulnerable to hypoglycemia and challenging to treat. Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart administered in a single injection, either once or twice daily with main meals.

Methods: A combined analysis of the phase 3 BOOST INTENSIFY PREMIX I (NCT01009580) and BOOST INTENSIFY ALL (NCT01059812) trials has previously reported lower rates of hypoglycemia during the maintenance period in patients with T2DM treated with IDegAsp twice daily (BID) versus biphasic insulin aspart 30 (BIAsp 30) BID. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0531-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349271PMC
February 2019
5 Reads

Reasonable Glycemic Control Would Help Wound Healing During the Treatment of Diabetic Foot Ulcers.

Diabetes Ther 2019 Feb 21;10(1):95-105. Epub 2018 Nov 21.

Department of Endocrine and Metabolism Disease, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Endocrine and Metabolism Disease, Shanghai, 200025, China.

Introduction: The effect of glycemic control on wound healing in patients with diabetic foot ulcers (DFUs) is inconsistent among different studies. This study was performed to investigate the association between level of hemoglobin A1c (HbA1c) at baseline as well as during treatment and wound healing and mortality in patients with DFU.

Methods: Hospitalized DFU patients were recruited consecutively with their basic clinical data collected and treated according to clinical practice guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0536-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349287PMC
February 2019
4 Reads